Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.47 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.47 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | OTC | P00480 | 1/20 | 0.45 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19952838 | 1.00 | GSR (0.66) | GSRLMNASMN1; SMN2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL19952846 | 1.00 | GSR (0.66) | GSRLMNASMN1; SMN2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL19953108 | 1.00 | GSR (0.66) | GSRLMNASMN1; SMN2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL19952984 | 1.00 | GSR (0.66) | GSRLMNASMN1; SMN2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL19952983 | 1.00 | GSR (0.66) | GSRLMNASMN1; SMN2GNAI3GNAO1 | |
| SCHEMBL19952847 | 0.98 | GSR (0.68) | GSRLMNASMN1; SMN2GNAI3GNAO1 | |
| SCHEMBL19952914 | 0.98 | GSR (0.68) | GSRLMNASMN1; SMN2GNAI3GNAO1 | |
| SCHEMBL19952912 | 0.98 | GSR (0.68) | GSRLMNASMN1; SMN2GNAI3GNAO1 | |
| SCHEMBL19952845 | 0.98 | GSR (0.68) | GSRLMNASMN1; SMN2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL19953118 | 0.96 | GSR (0.71) | GSRLMNASMN1; SMN2GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3509575-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | UNIV TEMPLE (US) | 2025-03-19 | — | — | EP | claimed |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-06-08 | — | — | US | claimed |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-03-07 | — | — | US | claimed |
| EP-4138812-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | Temple University - Of The Commonwealth System of Higher Education (US) | 2023-03-01 | — | — | EP | claimed |
| CN-115461049-A | (S) -2-amino-6- ((3-aminopropyl) amino) hexanoic Acid (APL) for the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | 坦普尔大学 | 2022-12-09 | — | — | CN | claimed |
| WO-2021217006-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-10-28 | — | — | WO | claimed |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-02-18 | — | — | US | claimed |
| US-12465582-B2 | (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4595969-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University Of The Commonwealth System Of Higher Education (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3509575-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | UNIV TEMPLE (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-06-08 | — | — | US | disclosed |
| CN-110139644-B | Compositions and methods for treating insulin resistance | 坦普尔大学 | 2023-05-23 | — | — | CN | disclosed |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210052532-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-02-18 | — | — | US | disclosed |
| CN-112088006-A | Compositions and methods for treating insulin resistance | 坦普尔大学 | 2020-12-15 | — | — | CN | disclosed |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of The Commonwealth Systems Of Higher Education (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3509575-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University Of The Commonwealth System Of Higher Education (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-06-27 | — | — | US | disclosed |
| WO-2018049019-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052532-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, FABP4, SLC2A3 | MAOA 3856/4885MAOB 2748/4885CA2 2387/4885 |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | MAOA 3612/4885MAOB 2092/4885CA2 3943/4885 |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | MAOA 3612/4885MAOB 2092/4885CA2 3943/4885 |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | MAOA 3612/4885MAOB 2092/4885CA2 3943/4885 |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | MAOA 3612/4885MAOB 2092/4885CA2 3943/4885 |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | FABP1, AADAT, FABP6 | MAOA 3850/4885MAOB 3471/4885CA2 4542/4885 |
| US-12465582-B2 | (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | FABP1, AADAT, FABP6 | MAOA 3850/4885MAOB 3471/4885CA2 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.